



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 84
- (48) Corrigendum issued on:
09.11.2005 Bulletin 2005/45
- (45) Date of publication and mention of the grant of the patent:
08.06.2005 Bulletin 2005/23
- (21) Application number: **00943847.4**
- (22) Date of filing: **22.06.2000**
- (51) Int Cl.7: **C07D 277/24, C07D 277/26, C07D 263/32, A61K 31/421, A61K 31/426, A61P 3/10**
- (86) International application number:
PCT/EP2000/005720
- (87) International publication number:
WO 2001/000603 (04.01.2001 Gazette 2001/01)

(54) **THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE**

THIAZOL- UND OXAZOL-DERIVATE UND IHRE PHARMAZEUTISCHE VERWENDUNG
DERIVES DE THIAZOL ET D'OXAZOLE ET UTILISATION PHARMACEUTIQUE DE CEUX-CI

- | | | | | | | | |
|--|--|----------------------|----------------------|----------------------|----------------------|------------------------|--|
| <p>(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
SI</p> <p>(30) Priority: 25.06.1999 GB 9914977</p> <p>(43) Date of publication of application:
27.03.2002 Bulletin 2002/13</p> <p>(73) Proprietor: SMITHKLINE BEECHAM CORPORATION
Philadelphia, Pennsylvania 19101 (US)</p> <p>(72) Inventors:
 <ul style="list-style-type: none"> • CHAO, Esther, Yu-Hsuan
Research Triangle Park, NC 27709 (US) • HAFFNER, Curt, Dale
Research Triangle Park, NC 27709 (US) • LAMBERT, Millard, Hurst, III
Research Triangle Park, NC 27709 (US) • MALONEY, Patrick, Reed
Research Triangle Park, NC 27709 (US) • SIERRA, Michael, Lawrence
91940 Les Ulis (FR) • STERNBACH, Daniel, David
Research Triangle Park, NC 27709 (US) • SZNAIDMAN, Marcos, Luis
Durham, NC 27713 (US) </p> | <ul style="list-style-type: none"> • WILLSON, Timothy, Mark
Research Triangle Park, NC 27709 (US) • XU, Huaqiang, Eric
Research Triangle Park, NC 27709 (US) • GELLIBERT, Françoise, Jeanne,
Lab. Glaxo Wellcome
91940 Les Ulis (FR) <p>(74) Representative: Learoyd, Stephanie Anne et al
GlaxoSmithKline
Two New
Horizons Court
Horizons Court
Brentford, Middlesex TW8 9GS (GB)</p> <p>(56) References cited:
 <table style="width: 100%; border: none;"> <tr> <td style="width: 50%;">WO-A-97/28149</td> <td style="width: 50%;">WO-A-98/07699</td> </tr> <tr> <td>WO-A-99/04815</td> <td>WO-A-99/46232</td> </tr> <tr> <td>US-A- 5 847 008</td> <td></td> </tr> </table> <ul style="list-style-type: none"> • PATENT ABSTRACTS OF JAPAN vol. 1997, no. 04, 30 April 1997 (1997-04-30) & JP 08 325250 A (SUMITOMO METAL IND LTD), 10 December 1996 (1996-12-10) -& JP 08 325250 A 10 December 1996 (1996-12-10) • H. SHINKAI ET AL.: JOURNAL OF MEDICINAL CHEMISTRY, vol. 41, no. 11, 1998, pages 1927-33, XP002151949 </p> | WO-A-97/28149 | WO-A-98/07699 | WO-A-99/04815 | WO-A-99/46232 | US-A- 5 847 008 | |
| WO-A-97/28149 | WO-A-98/07699 | | | | | | |
| WO-A-99/04815 | WO-A-99/46232 | | | | | | |
| US-A- 5 847 008 | | | | | | | |

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification